OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
Yanqiao Ren, Yusheng Guo, Lei Chen, et al.
Cancer Control (2022) Vol. 29
Open Access | Times Cited: 10
Yanqiao Ren, Yusheng Guo, Lei Chen, et al.
Cancer Control (2022) Vol. 29
Open Access | Times Cited: 10
Showing 10 citing articles:
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
Qiao Ke, Fuli Xin, Huipeng Fang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 38
Qiao Ke, Fuli Xin, Huipeng Fang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 38
The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
Nicolò Brandi, Matteo Renzulli
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8598-8598
Open Access | Times Cited: 22
Nicolò Brandi, Matteo Renzulli
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8598-8598
Open Access | Times Cited: 22
Survival of patients with non-viral hepatocellular carcinoma treated with trans-arterial chemoembolization: A multicenter cohort study
Hend Ibrahim Shousha, Eman Barakat, Eman Rewisha, et al.
Arab Journal of Gastroenterology (2025)
Closed Access
Hend Ibrahim Shousha, Eman Barakat, Eman Rewisha, et al.
Arab Journal of Gastroenterology (2025)
Closed Access
Effect of surgery on overall survival and cancer-specific survival in patients with primary HCC: A study based on PSM in the SEER cohort
Xia Lin, Shian Yu, Yuxian Bai, et al.
Medicine (2025) Vol. 104, Iss. 8, pp. e41521-e41521
Open Access
Xia Lin, Shian Yu, Yuxian Bai, et al.
Medicine (2025) Vol. 104, Iss. 8, pp. e41521-e41521
Open Access
Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A randomized clinical trial
Tan‐Yang Zhou, Guo-Fang Tao, Guan‐Hui Zhou, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 9, pp. 5527-5537
Open Access | Times Cited: 2
Tan‐Yang Zhou, Guo-Fang Tao, Guan‐Hui Zhou, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 9, pp. 5527-5537
Open Access | Times Cited: 2
Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review
Jingxin Yan, Manjun Deng, Shunyu Kong, et al.
iLiver (2022) Vol. 1, Iss. 4, pp. 225-234
Closed Access | Times Cited: 7
Jingxin Yan, Manjun Deng, Shunyu Kong, et al.
iLiver (2022) Vol. 1, Iss. 4, pp. 225-234
Closed Access | Times Cited: 7
The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy
Manzhou Wang, Limin Sun, Han Xinwei, et al.
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 47, Iss. 1, pp. 102060-102060
Closed Access | Times Cited: 4
Manzhou Wang, Limin Sun, Han Xinwei, et al.
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 47, Iss. 1, pp. 102060-102060
Closed Access | Times Cited: 4
Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis
Huimin Zou, Qing Lei, Xin Yan, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 260-260
Open Access | Times Cited: 3
Huimin Zou, Qing Lei, Xin Yan, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 260-260
Open Access | Times Cited: 3
Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
Zhang Xuexian, Ruidong Wang, Ding Yuhan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Zhang Xuexian, Ruidong Wang, Ding Yuhan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma
Hui Yang, Guang-Ping Qiu, Jie Liu, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 11, pp. 4392-4401
Closed Access
Hui Yang, Guang-Ping Qiu, Jie Liu, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 11, pp. 4392-4401
Closed Access
